Invivyd Stockholders Elect Directors, Ratify PwC at 2026 Annual Meeting

Invivyd (NASDAQ:IVVD) held its 2026 annual meeting of stockholders virtually, with Chairman of the Board Marc Elia presiding over the formal proceedings.

Elia called the meeting to order and said the virtual format allowed the company to reach a greater number of stockholders. Directors Tamsin Berry, Terrance McGuire and Kevin F. McLaughlin were present, along with Jill Andersen, Invivyd’s Chief Legal Officer and Corporate Secretary. Marc DeCoste attended as a representative of PricewaterhouseCoopers LLP, the company’s independent registered public accounting firm, and Stephen Nicolai of Hogan Lovells attended as outside corporate counsel.

Elia said Broadridge Financial Solutions, Inc. had certified that notice of internet availability of proxy materials was sent to all stockholders of record as of the close of business on March 20, 2026. He also noted that a quorum was present, with stockholders representing at least a majority of shares entitled to vote attending remotely or represented by proxy.

Stockholders Vote on Director Slate

The first proposal before stockholders was the election of six director nominees, each to serve a one-year term expiring at the 2027 annual meeting of stockholders. The nominees were Tamsin Berry, Paul B. Bolno, M.D., Marc Elia, Terrance McGuire, Kevin F. McLaughlin and Ajay Royan.

Elia said the board recommended that stockholders vote in favor of all named director nominees. According to preliminary results provided by the inspector of election, each of the six nominees was elected.

PwC Ratified as Independent Auditor

The second proposal was the ratification of PricewaterhouseCoopers LLP as Invivyd’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Elia said the board recommended stockholders vote in favor of the ratification.

Based on preliminary results, stockholders ratified the appointment of PricewaterhouseCoopers LLP. Elia said the results remain subject to final certification by the inspector of election.

No Stockholder Questions Submitted

During the meeting, stockholders were invited to submit questions through the web portal regarding the proposals and, after the formal business was adjourned, general questions about the company. Elia said no questions were submitted regarding the proposals, and no general stockholder questions were presented after adjournment of the formal portion of the meeting.

Elia said the company will report the final voting results in a Form 8-K to be filed with the Securities and Exchange Commission within four business days after the meeting.

The meeting concluded after the formal business was completed and the brief question-and-answer period ended with no questions submitted.

About Invivyd (NASDAQ:IVVD)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.